Erythrocytosis after allogeneic hematopoietic stem cell transplantation

Abstract

LETTER TO THE EDITOR allo-HSCT, EPO levels were in the normal range in all our patients, similar to Atilla's report. 1 Although reported risk factors for PTE among renal recipients are smoking, male gender, taking cyclosporine A, and post-transplant hypertension, 3 none of our patients had these factors except for male gender. Most patients in the present study were diagnosed after the withdrawal of CIs, similar to the previous report. 1 Interestingly, the primary diseases in the present study were only AA and MDS (RA), and no patients received chemotherapy before allo-HSCT.These results indicated that the mechanisms for development of PTE in allo-HSCT recipients likely differ from other transplant recipients, and some immunological mechanisms may affect PTE in allo-HSCT recipients. PTE following allo-HSCT is a rare complication, 1,4 and our small experience indicates the need for a larger series of patients to clarify the pathogenetic mechanisms of PTE in allo-HSCT recipients.

The Hct values after liver transplantation

“…Patients may require treatment with phlebotomy or angiotensinconverting enzyme inhibitors [4,5]. Acquired erythrocytosis was also described in subjects with simultaneous kidney-pancreas transplant [7] and those with allogeneic hematopoietic stem cell transplantation [8,9]. Based on our knowledge, our group was the first and only to report in 2013 [10] post-transplant erythrocytosis in subjects with liver transplantation.…”